In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 1	2026-08-20		NCT07775508

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chinese PLA General Hospital	238
Hebei Senlang Biotechnology Inc., Ltd.	14

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chinese PLA General Hospital, Beijing, Beijing 100853	Beijing	China	4

Clinical trials